Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

  • Gimenez, Neus
  • Tripathi, Rupal
  • Giró, Ariadna
  • Rosich, Laia
  • López-Guerra, Mónica
  • López-Oreja, Irene
  • Playa-Albinyana, Heribert
  • Arenas, Fabián
  • Mas, José Manuel
  • Pérez-Galán, Patricia
  • Delgado González, Julio
  • Campo, Elias
  • Farrés, Judith
  • Colomer Pujol, Dolors
Chronic lymphocytic leukemia (CLL) is a B lymphoid malignancy highly dependent on the microenvironment. Despite new targeted therapies such as ibrutinib and venetoclax, disease progression and relapse remain an issue. CLL cell interactions with the supportive tissue microenvironment play a critical role in disease pathogenesis. We used a platform for drug discovery based on systems biology and artificial intelligence, to identify drugs targeting key proteins described to have a role in the microenvironment. The selected compounds were screened in CLL cell lines in the presence of stromal cells to mimic the microenvironment and validated the best candidates in primary CLL cells. Our results showed that the commercial drug simvastatin was the most effective and selective out of the tested compounds. Simvastatin decreased CLL cell survival and proliferation as well as cell adhesion. Importantly, this drug enhanced the antitumor effect of venetoclax and ibrutinib. We proposed that systems biology approaches combined with pharmacological screening could help to find new drugs for CLL treatment and to predict new combinations with current therapies. Our results highlight the possibility of repurposing widely used drugs such as statins to target the microenvironment and to improve the efficacy of ibrutinib or venetoclax in CLL cells., The study was supported by research funding from the Spanish Ministry of Economy and Competitiveness through the Plan Estatal de Investigación Científica y Técnica y de Innovación (MINECO) RTI2018-094584-B-I00 [to DC] and was cofunded by the European Regional Development Fund [ERDF] and the CERCA program from Generalitat de Catalunya, Centro de Investigación Biomédica en Cáncer [CIBERONC] [CB16/12/00334 and CB16/12/00225] and Generalitat de Catalunya Suport Grups de Recerca [2017 SGR 1009]. This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 306240. NG is a recipient of a predoctoral fellowship from AGAUR, L.R. is a recipient of a postdoctoral fellowship from AGAUR (PERIS), ILO is a recipient of the PhD4MD program and HPA is a recipient of a predoctiral fellowship from Spanish Ministry of Economy and Competitiveness (FPU)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Network-based proteomic approaches reveal the neurodegenerative, neuroprotective and pain-related mechanisms involved after retrograde axonal damage

  • Casas, Caty
  • Isús Díaz, Laura, 1989-
  • Herrando Grabulosa, Mireia
  • Mancuso, Francesco M.
  • Borrás, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Forés, Joaquim
  • Aloy, Patrick, 1972-
Neurodegenerative processes are preceded by neuronal dysfunction and synaptic disconnection. Disconnection between spinal motoneuron (MN) soma and synaptic target leads either to a retrograde degenerative process or to a regenerative reaction, depending injury proximity among other factors. Distinguished key events associated with one or other processes may give some clues towards new therapeutical approaches based on boosting endogenous neuroprotective mechanisms. Root mechanical traction leads to retrograde MN degeneration, but share common initial molecular mechanisms with a regenerative process triggered by distal axotomy and suture. By 7 days post-injury, key molecular events starts to diverge and sign apart each destiny. We used comparative unbiased proteomics to define these signatures, coupled to a novel network-based analysis to get biological meaning. The procedure implicated the previous generation of combined topological information from manual curated 19 associated biological processes to be contrasted with the proteomic list using gene enrichment analysis tools. The novel and unexpected results suggested that motoneurodegeneration is better explained mainly by the concomitant triggering of anoikis, anti-apoptotic and neuropathic-pain related programs. In contrast, the endogenous neuroprotective mechanisms engaged after distal axotomy included specifically rather anti-anoikis and selective autophagy. Validated protein-nodes and processes are highlighted across discussion., This work was supported by grants from Fundació La marató-TV3 (#110432) who was funding all the present work and the postdoctoral fellowship of MHG. This work was partially supported by the European commission through the SyStemAge project (Agreement no: 306240). LI is a recipient of a PhD La Caixa fellowship.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

A chemo-centric view of human health and disease

  • Duran Frigola, Miquel
  • Rossell, David
  • Aloy, Patrick, 1972-
Efforts to compile the phenotypic effects of drugs and environmental chemicals offer the opportunity to adopt a chemo-centric view of human health that does not require detailed mechanistic information. Here we consider thousands of chemicals and analyse the relationship of their structures with adverse and therapeutic responses. Our study includes molecules related to the aetiology of 934 health-threatening conditions and used to treat 835 diseases. We first identify chemical moieties that could be independently associated with each phenotypic effect. Using these fragments, we build accurate predictors for approximately 400 clinical phenotypes, finding many privileged and liable structures. Finally, we connect two diseases if they relate to similar chemical structures. The resulting networks of human conditions are able to predict disease comorbidities, as well as identifying potential drug side effects and opportunities for drug repositioning, and show a remarkable coincidence with clinical observations.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Detecting similar binding pockets to enable systems polypharmacology

  • Duran Frigola, Miquel
  • Siragusa, Lydia
  • Ruppin, Eytan
  • Barril Alonso, Xavier
  • Cruciani, Gabriele
  • Aloy, Patrick, 1972-
In the era of systems biology, multi-target pharmacological strategies hold promise for tackling disease-related networks. In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacology of drugs can be anticipated by analyzing the similarity of binding sites across the proteome. Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands. By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacology. Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Mutations in RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

  • Giménez Carabaza, Neus
  • Martínez Trillos, Alejandra
  • Montraveta, Arnau
  • López-Guerra, Mónica
  • Rosich, Laia
  • Nadeu Prat, Ferran
  • Valero, Juan G.
  • Aymerich Gregorio, Marta
  • Magnano, Laura
  • Rozman, María
  • Matutes, Estella
  • Delgado, Julio (Delgado González)
  • Baumann, Tycho
  • Giné Soca, Eva
  • González, Marcos
  • Alcoceba, Miguel
  • Terol, Maria José
  • Navarro, Blanca
  • Colado, Enrique
  • Payer, Ángel R.
  • Puente, Xose S.
  • López-Otin, Carlos
  • López Guillermo, Armando
  • Campo Güerri, Elias
  • Colomer Pujol, Dolors
  • Villamor i Casas, Neus
Mutations in genes of the RAS-BRAF-MAPK-ERK pathwayhave not been fully explored in patients with chronic lym-phocytic leukemia. We, therefore, analyzed the clinical andbiological characteristics of chronic lymphocytic leukemia patientswith mutations in this pathway and investigated thein vitroresponseof primary cells to BRAF and ERK inhibitors. Putative damaging muta-tions were found in 25 of 452 patients (5.5%). Among these, BRAFwas mutated in nine patients (2.0%), genes upstream of BRAF(KITLG,KIT, PTPN11, GNB1, KRASand NRAS) were mutated in 12 patients(2.6%), and genes downstream of BRAF(MAPK2K1, MAPK2K2, andMAPK1) were mutated in five patients (1.1%). The most frequentmutations were missense, subclonal and mutually exclusive. Patientswith these mutations more frequently had increased lactate dehydro-genase levels, high expression of ZAP-70, CD49d, CD38, trisomy 12and unmutated immunoglobulin heavy-chain variable region genesand had a worse 5-year time to first treatment (hazard ratio 1.8,P=0.025). Gene expression analysis showed upregulation of genes ofthe MAPK pathway in the group carrying RAS-BRAF-MAPK-ERKpathway mutations. The BRAF inhibitors vemurafenib and dabrafenibwere not able to inhibit phosphorylation of ERK, the downstreameffector of the pathway, in primary cells. In contrast, ulixertinib, apan-ERK inhibitor, decreased phospho-ERK levels. In conclusion,although larger series of patients are needed to corroborate these find-ings, our results suggest that the RAS-BRAF-MAPK-ERK pathway isone of the core cellular processes affected by novel mutations inchronic lymphocytic leukemia, is associated with adverse clinical fea-tures and could be pharmacologically inhibited.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A proteome-scale map of the human interactome network

  • Rolland, Thomas
  • Fontanillo, Celia
  • De Las Rivas, Javier
  • Vidal, Marc
PMCID: PMC4266588.-- et al., Just as reference genome sequences revolutionized human genetics, reference maps of interactome networks will be critical to fully understand genotype-phenotype relationships. Here, we describe a systematic map of ∼14,000 high-quality human binary protein-protein interactions. At equal quality, this map is ∼30% larger than what is available from small-scale studies published in the literature in the last few decades. While currently available information is highly biased and only covers a relatively small portion of the proteome, our systematic map appears strikingly more homogeneous, revealing a >broader> human interactome network than currently appreciated. The map also uncovers significant interconnectivity between known and candidate cancer gene products, providing unbiased evidence for an expanded functional cancer landscape, while demonstrating how high-quality interactome models will help >connect the dots> of the genomic revolution., This work was supported primarily by NHGRI grant R01/U01HG001715 awarded to M.V., D.E.H., F.P.R., and J.T. and in part by the following grants and agencies: NHGRI P50HG004233 to M.V., F.P.R., and A.-L.B.; NHLBI U01HL098166 subaward to M.V.; NHLBI U01HL108630 subaward to A.-L.B.; NCI U54CA112962 subaward to M.V.; NCI R33CA132073 to M.V.; NIH RC4HG006066 to M.V., D.E.H., and T.H.; NICHD ARRA R01HD065288, R21MH104766, and R01MH105524 to L.M.I.; NIMH R01MH091350 to L.M.I. and T.H.; NSF CCF-1219007 and NSERC RGPIN-2014-03892 to Y.X.; Canada Excellence Research Chair, Krembil Foundation, Ontario Research Fund–Research Excellence Award, Avon Foundation, grant CSI07A09 from Junta de Castilla y Leon (Valladolid, Spain), grant PI12/00624 from Ministerio de Economia y Competitividad (AES 2012, ISCiii, Madrid, Spain), and grant i-Link0398 from Consejo Superior de Investigaciones Científicas (CSIC, Madrid, Spain) to J.D.L.R.; Spanish Ministerio de Ciencia e Innovación (BIO2010-22073) and the European Commission through the FP7 project SyStemAge grant agreement n: 306240 to P.A.; Group-ID Multidisciplinary Research Partnerships of Ghent University, grant FWO-V G.0864.10 from the Fund for Scientific Research-Flanders and ERC Advanced Grant N° 340941 to J.T.; EMBO long-term fellowship to A.K.; Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative to M.V. I.L. is a postdoctoral fellow with the FWO-V. M.V. is a “Chercheur Qualifié Honoraire” from the Fonds de la Recherche Scientifique (FRS-FNRS, Wallonia-Brussels Federation, Belgium). Since performing the work described, C. Fontanillo has become an employee of Celgene Research SL, part of the Celgene Corporation., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuroprotective drug for nerve trauma revealed using artificial intelligence

  • Romeo-Guitart, David
  • Forés, Joaquim
  • Herrando-Grabulosa, Mireia
  • Valls, Raquel
  • Leiva-Rodríguez, Tatiana
  • Galea, Elena
  • González-Pérez, Francisco
  • Navarro, Xavier
  • Petegnief, Valérie
  • Bosch, Assumpció
  • Coma, Mireia
  • Mas, José Manuel
  • Casas, Caty
Here we used a systems biology approach and artificial intelligence to identify a neuroprotective agent for the treatment of peripheral nerve root avulsion. Based on accumulated knowledge of the neurodegenerative and neuroprotective processes that occur in motoneurons after root avulsion, we built up protein networks and converted them into mathematical models. Unbiased proteomic data from our preclinical models were used for machine learning algorithms and for restrictions to be imposed on mathematical solutions. Solutions allowed us to identify combinations of repurposed drugs as potential neuroprotective agents and we validated them in our preclinical models. The best one, NeuroHeal, neuroprotected motoneurons, exerted anti-inflammatory properties and promoted functional locomotor recovery. NeuroHeal endorsed the activation of Sirtuin 1, which was essential for its neuroprotective effect. These results support the value of network-centric approaches for drug discovery and demonstrate the efficacy of NeuroHeal as adjuvant treatment with surgical repair for nervous system trauma., This work was mainly supported by a grant from Fundació La Marató-TV3 (#110432, CC, AB & VP) that funded the work and contracts of TLR and MHG and partially by the Ministerio de Economía y Competitividad of Spain (#SAF 2014-59701, CC, DRG, & TLR). We are also grateful for support from CIBERNED and funding from the European Union Seventh Framework Programme for research, technological development, and demonstration (#306240, XN, FRP & CC). Part of the research leading to these results has also received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 306240., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

  • Gimenez, Neus
  • Tripathi, Rupal
  • Giró, Ariadna
  • Rosich, Laia
  • López-Guerra, Mónica
  • López-Oreja, Irene
  • Playa-Albinyana, Heribert
  • Arenas, Fabián
  • Mas, José Manuel
  • Pérez-Galán, Patricia
  • Delgado González, Julio
  • Campo, Elias
  • Farrés, Judith
  • Colomer Pujol, Dolors
Chronic lymphocytic leukemia (CLL) is a B lymphoid malignancy highly dependent on the microenvironment. Despite new targeted therapies such as ibrutinib and venetoclax, disease progression and relapse remain an issue. CLL cell interactions with the supportive tissue microenvironment play a critical role in disease pathogenesis. We used a platform for drug discovery based on systems biology and artificial intelligence, to identify drugs targeting key proteins described to have a role in the microenvironment. The selected compounds were screened in CLL cell lines in the presence of stromal cells to mimic the microenvironment and validated the best candidates in primary CLL cells. Our results showed that the commercial drug simvastatin was the most effective and selective out of the tested compounds. Simvastatin decreased CLL cell survival and proliferation as well as cell adhesion. Importantly, this drug enhanced the antitumor effect of venetoclax and ibrutinib. We proposed that systems biology approaches combined with pharmacological screening could help to find new drugs for CLL treatment and to predict new combinations with current therapies. Our results highlight the possibility of repurposing widely used drugs such as statins to target the microenvironment and to improve the efficacy of ibrutinib or venetoclax in CLL cells., The study was supported by research funding from the Spanish Ministry of Economy and Competitiveness through the Plan Estatal de Investigación Científica y Técnica y de Innovación (MINECO) RTI2018-094584-B-I00 [to DC] and was cofunded by the European Regional Development Fund [ERDF] and the CERCA program from Generalitat de Catalunya, Centro de Investigación Biomédica en Cáncer [CIBERONC] [CB16/12/00334 and CB16/12/00225] and Generalitat de Catalunya Suport Grups de Recerca [2017 SGR 1009]. This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 306240. NG is a recipient of a predoctoral fellowship from AGAUR, L.R. is a recipient of a postdoctoral fellowship from AGAUR (PERIS), ILO is a recipient of the PhD4MD program and HPA is a recipient of a predoctiral fellowship from Spanish Ministry of Economy and Competitiveness (FPU)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mutations in RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

  • Giménez Carabaza, Neus
  • Martínez Trillos, Alejandra
  • Montraveta, Arnau
  • López-Guerra, Mónica
  • Rosich, Laia
  • Nadeu Prat, Ferran
  • Valero, Juan G.
  • Aymerich Gregorio, Marta
  • Magnano, Laura
  • Rozman, María
  • Matutes, Estella
  • Delgado, Julio (Delgado González)
  • Baumann, Tycho
  • Giné Soca, Eva
  • González, Marcos
  • Alcoceba, Miguel
  • Terol, Maria José
  • Navarro, Blanca
  • Colado, Enrique
  • Payer, Ángel R.
  • Puente, Xose S.
  • López-Otin, Carlos
  • López Guillermo, Armando
  • Campo Güerri, Elias
  • Colomer Pujol, Dolors
  • Villamor i Casas, Neus
Mutations in genes of the RAS-BRAF-MAPK-ERK pathwayhave not been fully explored in patients with chronic lym-phocytic leukemia. We, therefore, analyzed the clinical andbiological characteristics of chronic lymphocytic leukemia patientswith mutations in this pathway and investigated thein vitroresponseof primary cells to BRAF and ERK inhibitors. Putative damaging muta-tions were found in 25 of 452 patients (5.5%). Among these, BRAFwas mutated in nine patients (2.0%), genes upstream of BRAF(KITLG,KIT, PTPN11, GNB1, KRASand NRAS) were mutated in 12 patients(2.6%), and genes downstream of BRAF(MAPK2K1, MAPK2K2, andMAPK1) were mutated in five patients (1.1%). The most frequentmutations were missense, subclonal and mutually exclusive. Patientswith these mutations more frequently had increased lactate dehydro-genase levels, high expression of ZAP-70, CD49d, CD38, trisomy 12and unmutated immunoglobulin heavy-chain variable region genesand had a worse 5-year time to first treatment (hazard ratio 1.8,P=0.025). Gene expression analysis showed upregulation of genes ofthe MAPK pathway in the group carrying RAS-BRAF-MAPK-ERKpathway mutations. The BRAF inhibitors vemurafenib and dabrafenibwere not able to inhibit phosphorylation of ERK, the downstreameffector of the pathway, in primary cells. In contrast, ulixertinib, apan-ERK inhibitor, decreased phospho-ERK levels. In conclusion,although larger series of patients are needed to corroborate these find-ings, our results suggest that the RAS-BRAF-MAPK-ERK pathway isone of the core cellular processes affected by novel mutations inchronic lymphocytic leukemia, is associated with adverse clinical fea-tures and could be pharmacologically inhibited.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Detecting similar binding pockets to enable systems polypharmacology

  • Duran Frigola, Miquel
  • Siragusa, Lydia
  • Ruppin, Eytan
  • Barril Alonso, Xavier
  • Cruciani, Gabriele
  • Aloy, Patrick, 1972-
In the era of systems biology, multi-target pharmacological strategies hold promise for tackling disease-related networks. In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacology of drugs can be anticipated by analyzing the similarity of binding sites across the proteome. Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands. By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacology. Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Network-based proteomic approaches reveal the neurodegenerative, neuroprotective and pain-related mechanisms involved after retrograde axonal damage

  • Casas, Caty
  • Isús Díaz, Laura, 1989-
  • Herrando Grabulosa, Mireia
  • Mancuso, Francesco M.
  • Borrás, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Forés, Joaquim
  • Aloy, Patrick, 1972-
Neurodegenerative processes are preceded by neuronal dysfunction and synaptic disconnection. Disconnection between spinal motoneuron (MN) soma and synaptic target leads either to a retrograde degenerative process or to a regenerative reaction, depending injury proximity among other factors. Distinguished key events associated with one or other processes may give some clues towards new therapeutical approaches based on boosting endogenous neuroprotective mechanisms. Root mechanical traction leads to retrograde MN degeneration, but share common initial molecular mechanisms with a regenerative process triggered by distal axotomy and suture. By 7 days post-injury, key molecular events starts to diverge and sign apart each destiny. We used comparative unbiased proteomics to define these signatures, coupled to a novel network-based analysis to get biological meaning. The procedure implicated the previous generation of combined topological information from manual curated 19 associated biological processes to be contrasted with the proteomic list using gene enrichment analysis tools. The novel and unexpected results suggested that motoneurodegeneration is better explained mainly by the concomitant triggering of anoikis, anti-apoptotic and neuropathic-pain related programs. In contrast, the endogenous neuroprotective mechanisms engaged after distal axotomy included specifically rather anti-anoikis and selective autophagy. Validated protein-nodes and processes are highlighted across discussion., This work was supported by grants from Fundació La marató-TV3 (#110432) who was funding all the present work and the postdoctoral fellowship of MHG. This work was partially supported by the European commission through the SyStemAge project (Agreement no: 306240). LI is a recipient of a PhD La Caixa fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A chemo-centric view of human health and disease

  • Duran Frigola, Miquel
  • Rossell, David
  • Aloy, Patrick, 1972-
Efforts to compile the phenotypic effects of drugs and environmental chemicals offer the opportunity to adopt a chemo-centric view of human health that does not require detailed mechanistic information. Here we consider thousands of chemicals and analyse the relationship of their structures with adverse and therapeutic responses. Our study includes molecules related to the aetiology of 934 health-threatening conditions and used to treat 835 diseases. We first identify chemical moieties that could be independently associated with each phenotypic effect. Using these fragments, we build accurate predictors for approximately 400 clinical phenotypes, finding many privileged and liable structures. Finally, we connect two diseases if they relate to similar chemical structures. The resulting networks of human conditions are able to predict disease comorbidities, as well as identifying potential drug side effects and opportunities for drug repositioning, and show a remarkable coincidence with clinical observations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Network-based proteomic approaches reveal the neurodegenerative, neuroprotective and pain-related mechanisms involved after retrograde axonal damage

  • Casas Louzao, Caty|||0000-0002-2273-6321
  • Isus, Laura|||0000-0002-6308-5158
  • Herrando-Grabulosa, Mireia|||0000-0002-6685-3220
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Borràs, Eva|||0000-0002-3859-9907
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Forés Vineta, Joaquim|||0000-0003-1728-6212
  • Aloy, Patrick|||0000-0002-3557-0236
Neurodegenerative processes are preceded by neuronal dysfunction and synaptic disconnection. Disconnection between spinal motoneuron (MN) soma and synaptic target leads either to a retrograde degenerative process or to a regenerative reaction, depending injury proximity among other factors. Distinguished key events associated with one or other processes may give some clues towards new therapeutical approaches based on boosting endogenous neuroprotective mechanisms. Root mechanical traction leads to retrograde MN degeneration, but share common initial molecular mechanisms with a regenerative process triggered by distal axotomy and suture. By 7 days post-injury, key molecular events starts to diverge and sign apart each destiny. We used comparative unbiased proteomics to define these signatures, coupled to a novel network-based analysis to get biological meaning. The procedure implicated the previous generation of combined topological information from manual curated 19 associated biological processes to be contrasted with the proteomic list using gene enrichment analysis tools. The novel and unexpected results suggested that motoneurodegeneration is better explained mainly by the concomitant triggering of anoikis, anti-apoptotic and neuropathic-pain related programs. In contrast, the endogenous neuroprotective mechanisms engaged after distal axotomy included specifically rather anti-anoikis and selective autophagy. Validated protein-nodes and processes are highlighted across discussion.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

  • Giménez, N.
  • Martínez Trillos, A.
  • Montraveta, A.
  • Suárez Puente, Xosé Antón|||0000-0001-9525-1483
  • López Otín, Carlos|||0000-0001-6964-1904
This study was supported by the Ministerio de Economía y Competitividad, Grant n. SAF2015-67633-R ,and PI16/00420 which are part of Plan Nacional de I+D+I and are co-financed by the European Regional Development Fund (FEDER-“Una manera de hacer Europa”) and the CERCA program from Generalitat Catalunya. European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement n. 306240; Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR1009, and Departament de Salut (SLT002-16-00350), Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project), and project PM15/00007, which is part of Plan Nacional de I+D+I and are co-financed by FEDER. NG is a recipient of a predoctoral fellowship from Agaur and EC is an Academia Researcher of the "Institució Catalana de Recerca i Estudis Avançats" (ICREA) of the Generalitat de Catalunya., Giménez, N., Martínez-Trillos, A., Montraveta, A., Lopez-Guerra, M., Rosich, L., Nadeu, F., Valero, J.G., Aymerich, M., Magnano, L., Rozman, M., Matutes, E., Delgado, J., Baumann, T., Gine, E., González, M., Alcoceba, M., Terol, M.J., Navarro, B., Colado, E., Payer, A.R., Puente, X.S., López-Otín, C., Lopez-Guillermo, A., Campo, E., Colomer, D., Villamor, N.